Related Experiment Video

Updated: Jul 22, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

482

Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation

Carrie L Kitko1, Catherine M Bollard2,3,4, Mitchell S Cairo5

  • 1Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Pediatric Blood & Cancer
|July 21, 2023
PubMed

Insights

Pediatric cancer trials show tandem transplants improve survival for some tumors. Umbilical cord blood transplants are safer with one donor, and minimal residual disease predicts relapse risk in acute lymphoblastic leukemia.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Immunology

Background:

  • Children's Oncology Group trials have significantly advanced cellular therapy and stem cell transplantation since 2013.
  • New standards of care have been established for various pediatric cancers based on recent research.

Purpose of the Study:

  • To review key advancements in pediatric cellular therapy and stem cell transplantation.
  • To highlight findings that have shaped current treatment protocols.
  • To outline future directions in the field.

Main Methods:

  • Analysis of data from Children's Oncology Group cellular therapy-based clinical trials.
  • Review of survival outcomes, safety data, and predictive markers in pediatric cancer patients.

Main Results:

  • Tandem autologous transplants improved survival in neuroblastoma and atypical teratoid/rhabdoid brain tumors.
  • Single umbilical cord blood (UCB) donor transplants demonstrated improved safety compared to double UCB donor transplants.
  • Minimal residual disease (MRD) assessment pretransplant is a strong predictor of relapse in acute lymphoblastic leukemia (ALL).
  • Killer immunoglobulin receptor (KIR) mismatched donors did not enhance survival in pediatric acute myeloid leukemia (AML) with in vivo T-cell depletion.

Conclusions:

  • Cellular therapy and stem cell transplantation have evolved, setting new benchmarks in pediatric cancer care.
  • Future research will focus on optimizing donor selection, engineered cellular therapies, and managing treatment toxicities.
Keywords:
ALLAMLBMTCNS tumorsneuroblastoma

More Related Videos

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

6.7K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
360
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.5K